Immedica’s partner OrphanPacific initiates phase 3 trial with glycerol phenylbutyrate for treatment of urea cycle disorders in Japan
Stockholm, April 21 , 2023 - Immedica’s partner OrphanPacific Inc. (Tokyo, Japan) has enrolled the first patient in the phase 3 clinical trial with glycerol phenylbutyrate for the treatment of urea cycle disorders (UCD) in Japan. Immedica’s CEO Anders Edvell commented: “There is a significant medical need for better treatment options for people living with urea cycle disorders around the world. The initiation of this trial is a significant step towards expanding access to glycerol phenylbutyrate for patients in Japan.” This phase 3 clinical trial is planned to enroll 15 pediatric and